ATX
data caveat$80M—
Amplia Therapeutics
Biotech · Oncology
FAK inhibitor AMP945 for pancreatic and ovarian cancer
Data HealthTrials2 of 2 active · stale enrollment
No cash data on fileFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
—
Runway
—Market Cap
$80M
Burn Rate
—
Shares Outstanding
513M
Pipeline Assets
1
Latest Insights(2)
2 Apr 2026Insider TradeInitial Director's Interest Notice - Vernon
2 transactions·+$0k net buyVernon:
Insider TradeChange of Director's Interest Notice - George
1 transaction·+$0k net buyGeorge:
3M Price
ATX.ASX$0.155+10.7% 3M
Low $0.110High $0.265
Pipeline Assets (1)
AMP945Pancreatic cancer
Phase 1/2Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
AMP945
Pancreatic cancer
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Transactions
3 transactionsLast 90dNet Buy
Buys1+1 vs prior
Sells0
warningBlair Vernon bought 32d before "PHASE1/PHASE2 data readout — ACCENT: AMP945 in Combination with Nab-paclitaxel and Gemcitabine for Treatment "
2026-03-30
32d before · PHASE1/PHASE2 data readout — ACCENT: AMP945 in Combination with Nab-paclitaxel and Gemcitabine for Treatment
PERFORMANCE RIGHTS
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Competitive Landscape
1 approved drug586 competitor trialsPhase 2+ · Non-ASX
Pancreatic Cancer586 active trials
15 Ph464 Ph323 Ph2/3299 Ph2185 Ph1/PHASE2
Approved
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
Catalysts (2)
SpeculativeremoveMed1 May 2026
SpeculativeremoveMed1 July 2029
| Event | Type | Confidence | Impact | Date | Status |
|---|
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Track record will build as data accumulates — we need completed catalysts with original guidance dates, or at least two quarterly 4Cs, before scoring kicks in.
Clinical Trials(2)
2 activeClinicalTrials.gov ↗
Ph1/PHASE2RecruitingEnrollment stale · 247d
narmafotinib ascending dosesnarmafotinib dose comparison
A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer
Pancreatic Cancer Metastatic
18 Years+
Primary endpoint Number of Participants with Treatment-Emergent Adverse Events (TEAEs) from Baseline to End of Study
Ph1/PHASE2Active Not RecruitingEnrollment stale · 1422d
AMP945 ascending dosesAMP945 RP2D
ACCENT: AMP945 in Combination with Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer
Pancreatic Cancer · PDAC · Pancreatic Ductal Adenocarcinoma
18 Years+
Primary endpoint Number of Participants with Treatment-Emergent Adverse Events (TEAEs) from Baseline to End of Study
Announcements(18)
person
Insider Tradeauto_awesome
Initial Director's Interest Notice - Vernon2 Apr 2026
expand_more859KB